Jove
Visualize
お問い合わせ

関連する概念動画

CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

211
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
211
CRISPR01:59

CRISPR

52.9K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
52.9K
CRISPR and crRNAs02:53

CRISPR and crRNAs

17.3K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.3K
Homologous Recombination02:31

Homologous Recombination

51.5K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
51.5K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

6.1K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.1K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  2. 大腸がんにおけるcrispr/cas9:ゲノム編集と標的療法による精密腫瘍学の革命
  1. ホーム
  2. 大腸がんにおけるcrispr/cas9:ゲノム編集と標的療法による精密腫瘍学の革命

関連する実験動画

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

454

大腸がんにおけるCRISPR/Cas9:ゲノム編集と標的療法による精密腫瘍学の革命

Bahjat Alhasso1, Abdulkareem Shareef2, Lalji Baldaniya3

  • 1College of Pharmacy, Alnoor University, Nineveh, Iraq.

Iranian journal of basic medical sciences
|September 2, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

CRISPR/Cas9遺伝子編集は,がん細胞の遺伝子を正確に変えて結腸直腸がん (CRC) と戦う新しい方法を提供します. この技術は,腫瘍を抑制し,治療への反応を改善する臨床前モデルで有望であることが示されています.

キーワード:
CRISPR/Cas9について大腸がん (CRC) 遺伝子療法ゲノム編集腫瘍性経路腫瘍 抑制

さらに関連する動画

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

13.3K
A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells
10:07

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells

Published on: August 25, 2017

7.9K

関連する実験動画

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

454
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

13.3K
A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells
10:07

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells

Published on: August 25, 2017

7.9K

科学分野:

  • 遺伝学とゲノミクス
  • 腫瘍学
  • 分子生物学

背景:

  • 結腸直腸がん (CRC) は,革新的な分子療法を必要とする主要な世界的な健康問題です.
  • CRISPR/Cas9システムは 癌の研究における 精密なゲノム編集のための強力なプラットフォームを提供します

研究 の 目的:

  • 大腸がんの研究モデルにおけるCRISPR/Cas9技術の応用を検討する.
  • 腫瘍の進行を抑制し,治療感度を高める CRISPR/Cas9 の可能性を強調する.
  • CRISPR/Cas9の臨床翻訳における課題と将来の方向性を議論する.

主な方法:

  • CRISPR/Cas9をCRCモデル (MC38,CaCO-2) で標的遺伝子改変に使用した.
  • 癌細胞の増殖,アポトーシス,および化学反応に対する遺伝子ノックアウト (例えば,Par3L) の影響を調査した.
  • 特定CRCモデルにおけるアデノ関連ウイルス (AAV) 媒介のCRISPR編集を調査した.

主要な成果:

  • CRISPR/ Cas9遺伝子編集は,臨床前のCRCモデルで腫瘍抑制効果を示した.
  • Par3Lタンパク質のノックアウトは,増殖を抑制し,アポトーシスを誘導し,AMPKシグナル伝達によって化学療法に対する細胞を感知させました.
  • AAV媒介によるCRISPR編集は,HPV16駆動型CRCモデルで潜在性を示した.
  • 結論:

    • CRISPR/Cas9は 精密な遺伝子操作を可能にする CRCの研究のための 変革のツールです
    • 対象外効果や発症などの課題を克服することは 臨床翻訳において極めて重要です
    • CRISPR/Cas9は精密腫瘍学とパーソナライズされたCRC治療の進歩に大きな希望を持っています.